UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Prevention of Haemophilus influenzae type b infection

Author
Sylvia Yeh, MD
Section Editor
Sheldon L Kaplan, MD
Deputy Editor
Mary M Torchia, MD

INTRODUCTION

Haemophilus influenzae serotype b (Hib) was once the most common cause of bacterial meningitis and a frequent cause of other invasive diseases (eg, epiglottitis, pneumonia, septic arthritis, bacteremia), particularly in early childhood. The widespread use of Hib conjugate vaccines in infancy has led to a dramatic decline in the incidence of invasive Hib disease in children. However, invasive Hib disease remains common in countries not using the vaccine. Other strains of H. influenzae, particularly nontypeable H. influenzae (NTHi), cause mucosal and respiratory infections throughout life.

Active immunization and chemoprophylaxis for prevention of Hib infections will be discussed here. The microbiology and epidemiology of Haemophilus infections and the clinical syndromes caused by H. influenzae (typeable and nontypeable) in children and adults are discussed separately:

(See "Microbiology, epidemiology and treatment of Haemophilus influenzae".)

(See "Bacterial meningitis in children older than one month: Clinical features and diagnosis" and "Clinical features and diagnosis of acute bacterial meningitis in adults".)

(See "Epiglottitis (supraglottitis): Clinical features and diagnosis".)

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Feb 05 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014; 63:1.
  2. Tosi MF, Kaplan SL, Mason EO, et al. Generation of chemotactic activity in serum by Haemophilus influenzae type b. Infect Immun 1984; 43:593.
  3. Tarr PI, Hosea SW, Brown EJ, et al. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J Immunol 1982; 128:1772.
  4. Steele NP, Munson RS Jr, Granoff DM, et al. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect Immun 1984; 44:452.
  5. Newman SL, Waldo B, Johnston RB Jr. Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b. Infect Immun 1973; 8:488.
  6. Myerowitz RL, Norden CW. Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis. Infect Immun 1977; 16:218.
  7. Centers for Disease Control and Prevention. Current vaccine shortages and delays. Available at: www.cdc.gov/VACCINes/vac-gen/shortages/default.htm (Accessed on January 08, 2015).
  8. US Food and Drug Administration. Thimerosal in vaccines. www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228 (Accessed on October 12, 2015).
  9. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  10. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992; 121:355.
  11. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:97.
  12. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767.
  13. Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines 2011; 10:941.
  14. Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48.
  15. Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Hum Vaccin 2011; 7:258.
  16. Bryant K, McVernon J, Marchant C, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother 2012; 8:1036.
  17. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:e1375.
  18. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.
  19. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006; 296:671.
  20. Scheifele DW, Bettinger JA, Halperin SA, et al. Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007. Pediatr Infect Dis J 2008; 27:755.
  21. Langereis JD, de Jonge MI. Invasive Disease Caused by Nontypeable Haemophilus influenzae. Emerg Infect Dis 2015; 21:1711.
  22. ClinicalTrials.gov. Safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' nontypeable Haemophilus influenzae vaccine. https://clinicaltrials.gov/ct2/show/NCT01657526 (Accessed on October 12, 2015).
  23. ClinicalTrials.gov. Vaccination for middle ear infection. https://clinicaltrials.gov/ct2/show/NCT00001605 (Accessed on October 12, 2015).
  24. Murphy TF. Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now. Clin Vaccine Immunol 2015; 22:459.
  25. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184.
  26. Centers for Disease Control and Prevention (CDC). FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. MMWR Morb Mortal Wkly Rep 1997; 46:107.
  27. Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301.
  28. Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005; 4:793.
  29. American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.368.
  30. Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.
  31. Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.
  32. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.
  33. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187.
  34. Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484.
  35. Vella PP, Staub JM, Armstrong J, et al. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB). Pediatrics 1990; 85:668.
  36. Shapiro ED, Capobianco LA, Berg AT, Zitt MQ. The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J Infect Dis 1989; 160:1064.
  37. Yogev R, Arditi M, Chadwick EG, et al. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 1990; 85:690.
  38. Berrington JE, Cant AJ, Matthews JN, et al. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 2006; 117:e717.
  39. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186.
  40. Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275.
  41. Perrett KP, John TM, Jin C, et al. Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type B conjugate vaccination in early childhood and response to booster. Clin Infect Dis 2014; 58:949.
  42. Low N, Redmond SM, Rutjes AW, et al. Comparing Haemophilus influenzae type b conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. Pediatr Infect Dis J 2013; 32:1245.
  43. Jackson C, Mann A, Mangtani P, Fine P. Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data. Pediatr Infect Dis J 2013; 32:1261.
  44. Galil K, Singleton R, Levine OS, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179:101.
  45. Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006; 118:e421.
  46. Briere EC, Jackson M, Shah SG, et al. Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009. Pediatrics 2012; 130:414.
  47. Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics 1990; 86:102.
  48. Ahonkhai VI, Lukacs LJ, Jonas LC, Calandra GB. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein. Vaccine 1991; 9 Suppl:S38.
  49. Robinson CL, Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years--United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:86.
  50. Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273.
  51. Johnston RB Jr, Anderson P, Rosen FS, Smith DH. Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B. Clin Immunol Immunopathol 1973; 1:234.
  52. Norden CW. Prevalence of bactericidal antibodies to Haemophilus influenzae, type b. J Infect Dis 1974; 130:489.
  53. Stull TL, Jacobs RF, Haas JE, et al. Human serum bactericidal activity against Haemophilus influenzae type b. J Gen Microbiol 1984; 130:665.
  54. Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.
  55. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
  56. Edmonson MB, Granoff DM, Barenkamp SJ, Chesney PJ. Outer membrane protein subtypes and investigation of recurrent Haemophilus influenzae type b disease. J Pediatr 1982; 100:202.
  57. Holmes SJ, Lucas AH, Osterholm MT, et al. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group. JAMA 1991; 266:1960.
  58. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973.
  59. Centers for Disease Control and Prevention. Haemophilus influenzae type b. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on October 13, 2015).
  60. Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.
  61. World Health Organization. Haemophilus influenzae type b (Hib). www.who.int/immunization/diseases/hib/en/ (Accessed on November 11, 2015).
  62. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435.
  63. Gkentzi D, Collins S, Ramsay ME, et al. Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2013; 67:486.
  64. Li KI, Wald ER. Use of rifampin in Haemophilus influenzae type b infections. Am J Dis Child 1986; 140:381.
  65. Glode MP, Daum RS, Goldmann DA, et al. Haemophilus influenzae type B meningitis: a contagious disease of children. Br Med J 1980; 280:899.
  66. Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 1979; 301:122.
  67. Granoff DM, Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis 1980; 141:40.
  68. Band JD, Fraser DW, Ajello G. Prevention of Hemophilus influenzae type b disease. JAMA 1984; 251:2381.
  69. Glode MP, Daum RS, Halsey NA, et al. Rifampin alone and in combination with trimethoprim in chemoprophylaxis for infections due to Haemophilus influenzae type b. Rev Infect Dis 1983; 5 Suppl 3:S549.
  70. Granoff DM, Gilsdorf J, Gessert C, Basden M. Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin. Pediatrics 1979; 63:397.
  71. Glode MP, Daum RS, Boies EG, et al. Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts. Pediatrics 1985; 76:537.
  72. Shapiro ED, Wald ER. Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b. Pediatrics 1980; 66:5.
  73. Daum RS, Granoff DM, Gilsdorf J, et al. Haemophilus influenzae type b infections in day care attendees: implications for management. Rev Infect Dis 1986; 8:558.
  74. Ladhani S, Neely F, Heath PT, et al. Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2009; 58:3.
  75. Band JD, Fraser DW, Hightower AW, Broome CV. Prophylaxis of Hemophilus influenzae type b disease. JAMA 1984; 252:3249.
  76. Ogle JW, Rabalais GP, Glode MP. Duration of pharyngeal carriage of Haemophilus influenzae type b in children hospitalized with systemic infections. Pediatr Infect Dis 1986; 5:509.
  77. Murphy TV, Del Rio MA, Chrane D. Persistent pharyngeal colonization during therapy in patients with meningitis caused by Haemophilus influenzae type b. J Infect Dis 1985; 152:849.
  78. Goldwater PN. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children. Antimicrob Agents Chemother 1995; 39:2150.
  79. Prober CG. Effect of rifampin on chloramphenicol levels. N Engl J Med 1985; 312:788.
  80. Gessert C, Granoff DM, Gilsdorf J. Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease. Pediatrics 1980; 66:1.
  81. Mason EO Jr, Kaplan SL, Lamberth LB, et al. Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol 1982; 15:543.
  82. Ginsburg CM, McCracken GH Jr, Rae S, Parke JC Jr. Haemophilus influenzae type b disease. Incidence in a day-care center. JAMA 1977; 238:604.
  83. Horner DB, McCracken GH Jr, Ginsburg CM, Zweighaft TC. A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type b from the pharynx of infants and children. Pediatrics 1980; 66:136.
  84. Yogev R, Melick C, Kabat K. Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin. Pediatrics 1981; 67:430.
  85. Yogev R, Lander HB, Davis AT. Effect of TMP-SMX on nasopharyngeal carriage of ampicillin-sensitive and ampicillin-resistant hemophilus influenzae type B. J Pediatr 1978; 93:394.
  86. Kaplan SL, Mason EO Jr. Haemophilus influenzae type b disease in twins. J Pediatr 1983; 102:264.